OR WAIT null SECS
WuXi STA’s Delaware campus will contain clinical and commercial manufacturing capabilities for small molecules and novel molecular modalities.
WuXi STA, a contract development and manufacturing organization, and Delaware Prosperity Partnership announced plans for a pharmaceutical manufacturing campus in Middletown, Del.
Expected to open in 2024, the 190-acre campus in Middletown will be WuXi STA’s second site in the United States and will house pharmaceutical clinical and commercial manufacturing. The location will be the company’s eighth global manufacturing facility.
The company aims to bring 500 full-time positions to the Delaware complex by 2026, which has the potential to expand to a total workforce exceeding 1000 employees.
WuXi STA provides pharmaceutical development and manufacturing for more than 470 partners worldwide, covering small molecules and novel molecular modalities such as oligonucleotide, peptide, and complex conjugates.
Source: STA Pharma